Literature DB >> 17916100

Gene expression profiling of CD34+ cells in patients with the 5q- syndrome.

Jacqueline Boultwood1, Andrea Pellagatti, Helen Cattan, Charles H Lawrie, Aristoteles Giagounidis, Luca Malcovati, Matteo G Della Porta, Martin Jädersten, Sally Killick, Carrie Fidler, Mario Cazzola, Eva Hellström-Lindberg, James S Wainscoat.   

Abstract

The transcriptome of the CD34+ cells was determined in a group of 10 patients with the 5q- syndrome using a comprehensive array platform, and was compared with the transcriptome of CD34+ cells from 16 healthy control subjects and 14 patients with refractory anaemia and a normal karyotype. The majority of the genes assigned to the commonly deleted region (CDR) of the 5q- syndrome at 5q31-q32 showed a reduction in expression levels in patients with the 5q- syndrome, consistent with the loss of one allele. Candidate genes showing haploinsufficiency in the 5q- syndrome included the tumour suppressor gene SPARC and RPS14, a component of the 40S ribosomal subunit. Two genes mapping to the CDR, RBM22 and CSNK1A1, showed a >50% reduction in gene expression, consistent with the downregulation of the remaining allele. This study identified several significantly deregulated gene pathways in patients with the 5q- syndrome and gene pathway analysis data supports the proposal that SPARC may play a role in the pathogenesis of the 5q- syndrome. This study suggests that several of the genes mapping to the CDR of the 5q- syndrome play a role in the pathogenesis of this disorder.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17916100     DOI: 10.1111/j.1365-2141.2007.06833.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  51 in total

Review 1.  Molecular dissection of the 5q deletion in myelodysplastic syndrome.

Authors:  Benjamin L Ebert
Journal:  Semin Oncol       Date:  2011-10       Impact factor: 4.929

2.  The 5q- syndrome: biology and treatment.

Authors:  Eric Padron; Rami Komrokji; Alan F List
Journal:  Curr Treat Options Oncol       Date:  2011-12

3.  Haploinsufficient loss of multiple 5q genes may fine-tune Wnt signaling in del(5q) therapy-related myeloid neoplasms.

Authors:  Angela Stoddart; Joy Nakitandwe; Shann-Ching Chen; James R Downing; Michelle M Le Beau
Journal:  Blood       Date:  2015-11-13       Impact factor: 22.113

4.  Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase.

Authors:  Li Zhou; Christine McMahon; Tushar Bhagat; Cristina Alencar; Yiting Yu; Melissa Fazzari; Davendra Sohal; Christoph Heuck; Krishna Gundabolu; Chun Ng; Yongkai Mo; Wa Shen; Amittha Wickrema; Guanghui Kong; Ellen Friedman; Lubomir Sokol; Ioannis Mantzaris; Giannis Mantzaris; Andrea Pellagatti; Jacqueline Boultwood; Leonidas C Platanias; Ulrich Steidl; Lei Yan; Jonathan M Yingling; Michael M Lahn; Alan List; Markus Bitzer; Amit Verma
Journal:  Cancer Res       Date:  2010-12-28       Impact factor: 12.701

5.  Defective ribosome biogenesis in myelodysplastic syndromes.

Authors:  Naomi Galili; Samir Ahmed Qasim; Azra Raza
Journal:  Haematologica       Date:  2009-10       Impact factor: 9.941

Review 6.  [Pathobiology of the microRNA system].

Authors:  K Hussein
Journal:  Pathologe       Date:  2012-02       Impact factor: 1.011

7.  Reduced ribosomal protein gene dosage and p53 activation in low-risk myelodysplastic syndrome.

Authors:  Kelly A McGowan; Wendy W Pang; Rashmi Bhardwaj; Marcelina G Perez; John V Pluvinage; Bertil E Glader; Reem Malek; Susan M Mendrysa; Irving L Weissman; Christopher Y Park; Gregory S Barsh
Journal:  Blood       Date:  2011-07-25       Impact factor: 22.113

8.  MMP9 inhibition increases erythropoiesis in RPS14-deficient del(5q) MDS models through suppression of TGF-β pathways.

Authors:  Minyoung Youn; Haigen Huang; Cheng Chen; Sharon Kam; Mark C Wilkes; Hee-Don Chae; Kunju J Sridhar; Peter L Greenberg; Bertil Glader; Anupama Narla; Shuo Lin; Kathleen M Sakamoto
Journal:  Blood Adv       Date:  2019-09-24

Review 9.  Mechanism of action of lenalidomide in hematological malignancies.

Authors:  Venumadhav Kotla; Swati Goel; Sangeeta Nischal; Christoph Heuck; Kumar Vivek; Bhaskar Das; Amit Verma
Journal:  J Hematol Oncol       Date:  2009-08-12       Impact factor: 17.388

10.  A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome.

Authors:  Jillian L Barlow; Lesley F Drynan; Duncan R Hewett; Luke R Holmes; Silvia Lorenzo-Abalde; Alison L Lane; Helen E Jolin; Richard Pannell; Angela J Middleton; See Heng Wong; Alan J Warren; James S Wainscoat; Jacqueline Boultwood; Andrew N J McKenzie
Journal:  Nat Med       Date:  2009-11-22       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.